Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
Sign Up to like & getrecommendations! Published in 2019 at "EMBO Molecular Medicine"
DOI: 10.15252/emmm.201910293
Abstract: The majority of lung cancer patients progressing from conventional therapies are refractory to PD‐L1/PD‐1 blockade monotherapy. Here, we show that baseline systemic CD4 immunity is a differential factor for clinical responses. Patients with functional systemic… read more here.
Keywords: functional systemic; cd4 immunity; immunity; systemic cd4 ... See more keywords